Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 12/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25072986 | 0.90 | KDM4E (0.63) | ACLYPOLBKDM4EALDH1A1LMNA | |
| SCHEMBL25073139 | 0.90 | ACLY (0.73) | ACLYKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL25734189 | 0.87 | GAA (0.58) | POLBKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL25072656 | 0.86 | POLB (0.60) | POLBALDH1A1LMNARAD52 | |
| SCHEMBL25072952 | 0.85 | ACLY (0.67) | ACLYKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL25073310 | 0.84 | KMT2A (0.59) | ACLYPOLBALDH1A1LMNAMAPT | |
| SCHEMBL25734407 | 0.84 | MEN1 (0.59) | ACLYPOLBKDM4EALDH1A1LMNA | |
| SCHEMBL1138924 | 0.83 | CYP2C9 (0.63) | ACLYPOLBKDM4EALDH1A1LMNA | |
| SCHEMBL25072535 | 0.83 | ACLY (0.56) | ACLYALDH1A1LMNATDP1RAD52 | |
| SCHEMBL8711266 | 0.83 | POLB (0.78) | POLBALDH1A1KMT2ARAD52LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | ACLY 421/4885POLB 1547/4885KDM4E 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.